Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry.
- DOI
- 10.1002/ijc.35296
- Published
- 2025 May 1
- Container
- International journal of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/ijc.35296,
title = {Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry.},
author = {Thill M and Zahn MO and Welt A and Nusch A and Zaiss M and Engelken K and Kaltenecker G and Ringwald K and Gratzke K and Dille S and Kruggel L and Jänicke M and Schulz H and Hagen V and Fricker R and Stickeler E and Harbeck N and Wöckel A and Decker T},
year = {2025},
journal = {International journal of cancer},
doi = {10.1002/ijc.35296},
url = {https://doi.org/10.1002/ijc.35296}
}RIS
TY - JOUR TI - Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry. AU - Thill M AU - Zahn MO AU - Welt A AU - Nusch A AU - Zaiss M AU - Engelken K AU - Kaltenecker G AU - Ringwald K AU - Gratzke K AU - Dille S AU - Kruggel L AU - Jänicke M AU - Schulz H AU - Hagen V AU - Fricker R AU - Stickeler E AU - Harbeck N AU - Wöckel A AU - Decker T PY - 2025 JO - International journal of cancer DO - 10.1002/ijc.35296 UR - https://doi.org/10.1002/ijc.35296 ER -
APA
M, T., MO, Z., A, W., A, N., M, Z., K, E., G, K., K, R., K, G., S, D., L, K., M, J., H, S., V, H., R, F., E, S., N, H., A, W., & T, D. (2025). Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry.. International journal of cancer. https://doi.org/10.1002/ijc.35296
Source records
- pubmed · retrieved 2026-09-25T17:10:03.790Z